Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Genfit SA (GNFT) and Biora Therapeutics (BIOR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Genfit SA (GNFT – Research Report) and Biora Therapeutics (BIOR – Research Report) with bullish sentiments.

Altimmune (ALT)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune today and set a price target of $50.00. The company’s shares closed last Thursday at $14.96.

According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.6% and a 33.8% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $29.57, a 98.2% upside from current levels. In a report issued on January 17, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Genfit SA (GNFT)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA today and set a price target of $8.00. The company’s shares closed last Thursday at $4.25.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.9% and a 44.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Genfit SA is a Moderate Buy with an average price target of $8.00.

Biora Therapeutics (BIOR)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics, with a price target of $65.00. The company’s shares closed last Thursday at $4.17, close to its 52-week low of $1.95.

According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.0% and a 35.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biora Therapeutics with a $65.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALT:

• Altimmune management to meet virtually with Piper Sandler
• Altimmune price target raised to $25 from $14 at Evercore ISI
• Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
• Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
• Altimmune Appoints Raymond Jordt as Chief Business Officer